Edwards Lifesciences (EW) Long-Term Investments (2009 - 2026)

Edwards Lifesciences has reported Long-Term Investments for 18 years, with the latest figure at $244.1 million in Q2 2026.

• On a quarterly basis, Long-Term Investments fell 18.22% year-over-year to $244.1 million in Q2 2026; TTM through Jun 2026 was $244.1 million, a 18.22% decrease from a year earlier, with the FY2025 full-year figure at $278.6 million, down 9.52% from the prior year.
• Long-Term Investments was $244.1 million for Q2 2026 at Edwards Lifesciences, down from $285.6 million in the prior quarter.
• The five-year high for Long-Term Investments was $1.6 billion in Q1 2022, with the low at $244.1 million in Q2 2026.
• Average Long-Term Investments over 5 years is $669.0 million, with a median of $404.4 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Long-Term Investments surged 102.41% in 2022, then tumbled 58.74% in 2024.
• Over 5 years, Long-Term Investments stood at $1.2 billion in 2022, then tumbled by 52.87% to $583.9 million in 2023, then plunged by 47.27% to $307.9 million in 2024, then decreased by 9.52% to $278.6 million in 2025, then slipped by 12.38% to $244.1 million in 2026.
• The last three Long-Term Investments figures came in at $244.1 million (Q2 2026), $285.6 million (Q1 2026), and $278.6 million (Q4 2025), per Business Quant data.